Treating ALK-positive non-small cell lung cancer

Targeting genomic alterations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements, have radically changed the treatment of patients with non-small cell lung cancer (NSCLC). In the case of ALK-rearranged gene, subsequent rapid developmen...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Transl Med
Asıl Yazarlar: Ziogas, Dimitrios C., Tsiara, Anna, Tsironis, Georgios, Lykka, Maria, Liontos, Michalis, Bamias, Aristotelis, Dimopoulos, Meletios-Athanasios
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2018
Konular:
Review Article on Breakthroughs in the Treatment of Advanced Lung Cancer: Making Progress Through Innovation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5952030/
https://ncbi.nlm.nih.gov/pubmed/29862230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2017.11.34
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller